logo
  

Pentair Plc Updates FY18 Guidance To Reflect Separation Of Electrical Business

Pentair plc (PNR) updated its estimated 2018 GAAP EPS from continuing operations to approximately $1.83 and on an adjusted EPS basis to approximately $2.33. The company updated sales guidance to $2.96 billion, up 4 to 5 percent on a reported and core basis, respectively, over 2017. In July, the company projected: GAAP EPS from continuing operations to approximately $1.81 and on an adjusted EPS basis to approximately $2.31; and sales of $2.95 billion. The company noted that guidance update reflects the separation of its Electrical business, on April 30, 2018 and the reporting of Electrical's results as discontinued operations.

For the fourth quarter, the company expects GAAP EPS from continuing operations of approximately $0.55 and on an adjusted EPS basis of approximately $0.59. The company expects fourth quarter sales to be approximately $736 million, up 1 to 2 percent on a reported basis and up 4 to 5 percent on a core basis compared to fourth quarter 2017.

For the third-quarter, on an adjusted basis, the company reported EPS of $0.54 compared to $0.49 in the third quarter of 2017. Sales were $711 million, up 3 percent compared to sales for the same period last year. Excluding currency translation, acquisitions and divestitures, core sales grew 6 percent in the third quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT